Somatostatin 5 receptor expression in prolactinomas: Is there a role for Pasireotide in the management of prolactinomas?
Study context
- Population
- Patients with prolactinomas undergoing surgery; 22 of 34 dopamine agonists (DA)-resistant
- Participants
- 34 patients
- Exposure
- Expression of D2R, SST2 and SST5 receptors; in vitro effects of cabergoline, octreotide and pasireotide on prolactin production
- Outcome
- Receptor expression (IRS) in surgical specimens
Methodological detailstwo-center, in vitro experiments on cultured prolactinoma cells
- Two-center
- In vitro experiments on cultured prolactinoma cells
Main finding
As reported in the abstract
D2R expression
97.1%
SST5 expression
70.6%
SST2 expression
41.2%
Observational data: associations, not effects.
Further findings
Preoperative DA use and DA resistance
- Used DA preoperatively
- 31/34(91%)
- DA-resistant
- 22/34(64.7%)
In vitro potency on prolactin secretion
- Octreotide least potent, cabergoline most potent
- In a subgroup, pasireotide inhibited prolactin secretion with comparable potency to cabergoline
Receptor immunoreactivity score (IRS) by in vitro response
- Median D2R IRS, <50% vs >50% inhibition by cabergoline
- 1.0 vs 8.0
- Median SST5 IRS, <50% vs >50% inhibition by pasireotide
- 3.5 vs 12.0
Original publication
Somatostatin 5 receptor expression in prolactinomas: Is there a role for Pasireotide in the management of prolactinomas? Pituitary. Published 3 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →